Total Payments
$121,181
2024 Payments
$6,116
Companies
20
Transactions
98
Medicare Patients
15,226
Medicare Billing
$15.3M
Payment Breakdown by Category
Consulting$79,603 (65.7%)
Other$35,841 (29.6%)
Travel$3,018 (2.5%)
Food & Beverage$2,719 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $79,603 | 21 | 65.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,566 | 7 | 26.0% |
| Honoraria | $4,275 | 3 | 3.5% |
| Travel and Lodging | $3,018 | 7 | 2.5% |
| Food and Beverage | $2,719 | 60 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Baxter Healthcare | $47,585 | 10 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $33,925 | 21 | $0 (2024) |
| Genentech USA, Inc. | $11,994 | 17 | $0 (2024) |
| Carl Zeiss Meditec, Inc. | $8,000 | 1 | $0 (2019) |
| Alcon Vision LLC | $5,697 | 7 | $0 (2024) |
| TOPCON HEALTHCARE SOLUTIONS, INC. | $5,000 | 1 | $0 (2020) |
| Ellex, Inc | $4,017 | 2 | $0 (2020) |
| Genentech, Inc. | $3,207 | 2 | $0 (2020) |
| ABBVIE INC. | $555.41 | 19 | $0 (2024) |
| Welch Allyn | $275.00 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,116 | 27 | Alcon Vision LLC ($5,506) |
| 2023 | $3,977 | 8 | Genentech USA, Inc. ($3,802) |
| 2022 | $55,664 | 17 | Baxter Healthcare ($47,585) |
| 2021 | $86.69 | 4 | Alcon Vision LLC ($41.80) |
| 2020 | $22,958 | 9 | Regeneron Healthcare Solutions, Inc. ($14,715) |
| 2019 | $27,384 | 22 | Regeneron Healthcare Solutions, Inc. ($19,005) |
| 2018 | $4,283 | 4 | Ellex, Inc ($4,000) |
| 2017 | $711.97 | 7 | Allergan Inc. ($229.17) |
All Payment Transactions
98 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: EYE CARE | ||||||
| 12/18/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $6.02 | General |
| Category: EYE CARE | ||||||
| 12/16/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: EYE CARE | ||||||
| 12/06/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $5.41 | General |
| Category: EYE CARE | ||||||
| 11/06/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: EYE CARE | ||||||
| 11/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/16/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: EYE CARE | ||||||
| 10/10/2024 | Glaukos Corporation | iDose (Device) | Food and Beverage | Cash or cash equivalent | $121.30 | General |
| Category: Glaucoma | ||||||
| 10/02/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $39.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/11/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: EYE CARE | ||||||
| 09/06/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $23.34 | General |
| 09/04/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Ophthalmology | ||||||
| 08/21/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/14/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $34.42 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/01/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $106.00 | General |
| Category: Ophthalmology | ||||||
| 06/26/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: EYE CARE | ||||||
| 06/12/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: EYE CARE | ||||||
| 06/10/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $3.56 | General |
| Category: EYE CARE | ||||||
| 05/23/2024 | Alcon Vision LLC | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 05/22/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: EYE CARE | ||||||
| 05/22/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.81 | General |
| Category: EYE CARE | ||||||
| 05/15/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/02/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $28.76 | General |
| Category: EYE CARE | ||||||
| 04/10/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 3,473 | 70,961 | $12.5M | $4.6M |
| 2022 | 24 | 3,829 | 27,575 | $9.9M | $4.3M |
| 2021 | 20 | 3,742 | 13,365 | $8.3M | $3.8M |
| 2020 | 23 | 4,182 | 12,627 | $5.7M | $2.7M |
Total Patients
15,226
Total Services
124,528
Medicare Billing
$15.3M
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 194 | 59,760 | $4.6M | $1.7M | 37.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 236 | 2,352 | $3.9M | $1.6M | 41.2% |
| J3490 | Unclassified drugs | Office | 2023 | 71 | 289 | $2.8M | $512,149 | 18.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 443 | 2,109 | $374,287 | $210,407 | 56.2% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 28 | 900 | $187,497 | $108,324 | 57.8% |
| 92134 | Imaging of retina | Office | 2023 | 917 | 2,858 | $135,343 | $84,211 | 62.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 453 | 785 | $129,030 | $74,052 | 57.4% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 27 | 357 | $115,717 | $55,810 | 48.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 527 | 747 | $75,312 | $42,478 | 56.4% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 38 | 38 | $49,786 | $31,654 | 63.6% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 38 | 45 | $46,444 | $28,310 | 61.0% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 81 | 229 | $28,813 | $15,452 | 53.6% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 14 | 68 | $23,757 | $14,568 | 61.3% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 11 | 14 | $17,107 | $11,528 | 67.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 96 | 96 | $20,412 | $11,264 | 55.2% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 21 | 22 | $14,305 | $8,552 | 59.8% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 63 | 63 | $10,219 | $6,288 | 61.5% |
| 67031 | Release of scar tissue between lens and retina using a laser | Office | 2023 | 15 | 15 | $7,733 | $4,633 | 59.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 34 | 35 | $5,007 | $3,373 | 67.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 32 | 32 | $4,506 | $2,276 | 50.5% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 40 | 51 | $4,007 | $1,677 | 41.9% |
| 92250 | Photography of the retina | Office | 2023 | 50 | 51 | $2,251 | $1,361 | 60.4% |
| 92274 | Measurement of retinal and optic nerve function targeting multiple separate locations | Office | 2023 | 16 | 17 | $1,580 | $1,085 | 68.7% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 28 | 28 | $1,670 | $595.84 | 35.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 314 | 4,030 | $6.9M | $2.9M | 42.0% |
About Dr. Peter Karth, MD
Dr. Peter Karth, MD is a Retina Specialist healthcare provider based in North Bend, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/05/2010. The National Provider Identifier (NPI) number assigned to this provider is 1508181355.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Karth, MD has received a total of $121,181 in payments from pharmaceutical and medical device companies, with $6,116 received in 2024. These payments were reported across 98 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($79,603).
As a Medicare-enrolled provider, Karth has provided services to 15,226 Medicare beneficiaries, totaling 124,528 services with total Medicare billing of $15.3M. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Location North Bend, OR
- Active Since 04/05/2010
- Last Updated 06/30/2025
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1508181355
Products in Payments
- Hillrom - RetinaVue 700 Imager (Device) $47,585
- EYLEA (Biological) $33,735
- FORUM (Device) $8,000
- VABYSMO (Drug) $7,294
- RDX (Device) $5,000
- Lucentis (Biological) $4,042
- Tango-R SLT/YAG Combination Laser with Reflex Technology (Device) $4,017
- Vabysmo (Drug) $3,865
- OZURDEX (Drug) $369.06
- Constellation (Device) $310.29
- RetinaVue Network (Device) $275.00
- Humira (Biological) $201.56
- EYLEA AFLIBERCEPT INJECTION (Biological) $141.17
- iDose (Device) $121.30
- BEOVU (Drug) $94.36
- EYLEA HD (Biological) $74.40
- BROLUCIZUMAB (Drug) $42.67
- Syfovre (Drug) $24.97
- YUTIQ (Drug) $24.68
- INVELTYS (Drug) $23.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.